Journal of Clinical Oncology
Articles in this Issue
Exploring transportation insecurity among cancer patients in urban cancer clinics in Ontario, Canada.
1538 Background: Advancements in cancer therapeutics have led to increasing care complexity, higher visit frequency, and i...
A phase II multicenter study of NASOX regimen as adjuvant chemotherapy for patients with resected pancreatic ductal adenocarcinoma.
4230 Background: Pancreatic ductal adenocarcinoma (PDAC) is the fifth leading cause of cancer-related mortality in China,...
Impact of a real-time updated evidence library in addressing lag in guideline updates to aide physicians.
e13684 Background: Across oncology, practice-changing data emerges daily from peer-reviewed publications, major congresses...
Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD ± rituximab (R) in patients (pts) with relapsed/refractory (R/R) follicular lymphoma (FL): Long-term follow-up (f/u) of the phase (Ph) 1/2 CC-99282-NHL-001 study.
e19046 Background: While outcomes in pts with R/R FL have improved with current SOC treatments (Tx), there remains a need...
Real-world evidence of tazemetostat in epithelioid sarcoma patients.
e23539 Background: Epithelioid sarcoma (ES) is an ultra-rare and aggressive mesenchymal soft tissue sarcoma (STS) with lim...
PIN1, cholesterol biosynthesis, and clinical outcomes in urothelial carcinoma (UC): A propensity-weighted real-world clinicogenomic analysis.
e16575 Background: PIN1 is a phosphorylation-dependent prolyl isomerase that regulates oncogenic pathways, including cance...
A health systems analysis of global head and neck cancer outcomes.
e18092 Background: Head and neck cancers (HNC) remain a major global cause of cancer morbidity and mortality, with disprop...
Phase 2b randomized, blinded, placebo-controlled trial to investigate the efficacy and safety of visugromab added to pembrolizumab, pemetrexed, and carboplatin in first-line metastatic non-squamous NSCLC: GDFATHER-NSCLC-01.
TPS8665 Background: Immune checkpoint inhibitors (ICIs) have improved outcomes in NSCLC, yet primary and secondary resista...
OPERA-02: A phase 3 study of palazestrant plus ribociclib as first-line treatment of ER+, HER2- advanced breast cancer.
TPS1152 Background: Estrogen receptor-positive, human epidermal growth factor 2-negative advanced breast cancer (ER+, HER2...
A phase 1/2, multi-center, open-label study to evaluate the safety, tolerability, pharmacokinetics, radiation dosimetry, and preliminary anti-neoplastic activity of LNTH-2403, a LRRC15-targeted <sup>177</sup> lutetium-labeled monoclonal antibody, in patients with relapsed/refractory osteosarcoma.
TPS11587 Background: Treatment for relapsed and refractory (R/R) osteosarcoma (OST) has not changed for decades. R/R OST h...
Real-world study on the effect of PARPi as maintenance therapy on recurrent site after first-line chemotherapy in patients with high-grade serous epithelial ovarian cancer.
e17593 Background: This study investigated the effect of poly (ADP-ribose) polymerase inhibitors (PARPi) as maintenance th...
Impact of transfusion timing on clinical outcomes across hematologic malignancies.
e18613 Background: Transfusion support is essential in the inpatient management of hematologic malignancies; however, dise...
Association of triple-negative breast cancer with decreased T score of femoral neck at the time of osseous metastasis.
e13132 Background: While agents are administered when indicated, skeletal vulnerability may vary ; however, molecular subt...
Defining the role of locoregional radiotherapy for de novo metastatic nasopharyngeal carcinoma in the immunotherapy era: A systematic review and meta-analysis.
6039 Background: In the pre-immunotherapy era, a phase 3 randomized controlled trial (NCT02111460) confirmed locoregional...
Real-world outcomes of abiraterone in metastatic prostate cancer: A multicenter study in Peru.
e23405 Background: Prostate cancer accounts for 14% of cancers in men in Peru. Although abiraterone acetate was approved b...
Clonal hematopoiesis as a predictor of immune toxicity and efficacy after chimeric antigen receptor T-cell therapy: A systematic review and meta-analysis.
7039 Background: Clonal hematopoiesis of indeterminate potential (CHIP) is associated with age-related inflammation and ma...
LuSato-1: Phase I study of <sup>177</sup> Lu-SSO110 with <sup>68</sup> Ga-SSO120 companion imaging in patients with extensive stage small cell lung cancer (ES-SCLC) on maintenance treatment with immune checkpoint inhibition (ICI).
8011 Background: Outcomes for pts with ES-SCLC remains suboptimal despite the addition of ICIs to platinum-based chemother...
Association of GLP-1 agonists with breast cancer incidence in women.
10506 Background: Excess weight is a key modifiable risk factor for breast cancer. Glucagon-like peptide-1 receptor agonis...
High-dose furmonertinib in <i>EGFR</i> -mutated advanced NSCLC with brain metastases after EGFR-TKI resistance: The iFORCE phase II trial.
8607 Background: Brain metastases (BM) are common in patients with EGFR...
Potential BMI-dependent overall survival differences in postmenopausal breast cancer patients treated with CDK4/6 inhibitors: A Mayo Clinic platform study.
1110 Background: CDK4/6 inhibitors with endocrine therapy are widely used for HR+/HER2– metastatic breast cancer (BC). Whi...
National inpatient burden of nausea, vomiting, and dehydration during radiotherapy: A HCUP NIS analysis.
e24198 Background: Even when radiotherapy is delivered outpatient, treatment-related nausea, vomiting, and dehydration can...
Missed by the guidelines: A meta-analysis of USPSTF lung cancer screening ineligibility among patients diagnosed with lung cancer.
10573 Background: Lung cancer (LC) screening utilizes low-dose CT recommended by the US Preventive Services Task Force (US...
Modern concepts of endometrial squamous cell carcinoma.
e17626 Background: Endometrial cancer is the leading oncogynecological malignancy, with a concerning trend of shifting age...
Efficacy and safety of AKT inhibitor NTQ1062 combined with fulvestrant in patients with HR-positive/HER2-negative metastatic breast cancer：a proof-of-concept, multicenter, open-label, nonrandomized, phase Ib/II study.
e13043 Background: NTQ1062 is an oral, potent, and pan-AKT small-molecule inhibitor with favorable pharmacokinetic propert...
Optimal timing of endocrine therapy interruption for pregnancy in young women with hormone receptor–positive early breast cancer.
627 Background: The POSITIVE trial showed that temporary interruption of adjuvant endocrine therapy (ET) after 18–30 month...